TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response

  title={TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response},
  author={Ming-Fen Ho and Chi Zhang and Lingxin Zhang and Lixuan Wei and Ying Zhou and Irene Moon and Jennifer R. Geske and Doo‐Sup Choi and Joanna M. Biernacka and Mark A. Frye and Zhexing Wen and Victor M. Karpyak and Hu Li and Richard M. Weinshilboum},
  journal={Molecular Psychiatry},
  pages={3122 - 3133}
We previously reported that SNPs near TSPAN5 were associated with plasma serotonin (5-HT) concentrations which were themselves associated with selective serotonin reuptake inhibitor treatment outcomes in patients with major depressive disorder (MDD). TSPAN5 SNPs were also associated with alcohol consumption and alcohol use disorder (AUD) risk. The present study was designed to explore the biological function of TSPAN5 with a focus on 5-HT and kynurenine concentrations in the tryptophan pathway… 

Figures from this paper

Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction
Application of a multiple omics research strategy that used metabolomics to inform genomics, followed by functional genomic studies, identified novel genes that influenced monoamine biology and made it possible to develop a predictive algorithm for SSRI clinical outcomes in MDD.
Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication
It is suggested that integrating specific metabolites and SNPs achieves accurate predictions of treatment response across classes of antidepressants, and motivates functional investigation into how sphingomyelins might influence MDD pathophysiology, antidepressant response, or both.
Making Sense of Patient-Derived iPSCs, Transdifferentiated Neurons, Olfactory Neuronal Cells, and Cerebral Organoids as Models for Psychiatric Disorders
This review aims to provide an overview of all these models using neurons generated from induced pluripotent stem cells as well as directly induced neurons, cerebral organoids, and olfactory neuroepithelium to make sense of the current literature.


TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
Application of a pharmacometabolomics-informed pharmacogenomic research strategy, followed by functional validation, indicated that TSPAN5 and ERICH3 are associated with plasma serotonin concentrations and may have a role in SSRI treatment outcomes.
Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons
The results suggest that intrinsic differences in serotonergic neuron morphology and the resulting circuitry may contribute to SSRI resistance in MDD patients.
Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects
Elevated baseline serum glutamate levels are demonstrated to be a potential biomarker associated with positive acamprosate response, which is an important step towards development of a personalized approach to treatment for AUD.
Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics
A metabolomics-informed genomic research strategy was applied to study the contribution of genetic variation to MDD pathophysiology by assaying 31 metabolites and identifying SNPs that were cis-eQTLs for DEFB1 and AHR and, which were associated with variation in plasma KYN concentrations that were related to severity of MDD symptoms.
Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons
The data suggest that postsynaptic forebrain hyperactivity downstream of SSRI treatment may play a role in SSRI resistance in MDD, and patient stratification based on pharmacological responsiveness and the use of patient-derived neurons may make possible the discovery of disease-relevant neural phenotypes.
Pharmacogenetics of alcohol and alcohol dependence treatment.
Because parallel developments in alcoholism treatment and the genetics of alcohol dependence are beginning to converge, using genotypic information, it may be possible to match patients with specific treatments, and of greatest clinical relevance is the finding that the presence of an Asp40 allele in OPRM1 modestly predicts a better response to naltrexone treatment.
Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy.
Despite a trend towards reduced kynurenine concentrations in those who responded to ketamine, ketamine was not associated with significant alterations in any of the biomarkers assessed.
Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia
Further evidence is provided for the role of inflammation in a subgroup of patients with schizophrenia and a molecular mechanism through which inflammation could lead to schizophrenia is suggested.
Inflammatory responses to alcohol in the CNS: nuclear receptors as potential therapeutics for alcohol‐induced neuropathologies
The evidence of alcohol‐induced CNS inflammation is summarized, cellular and molecular mechanisms that may underlie alcohol induction of CNS inflammation are outlined, and the potential of nuclear receptor agonists for prevention or treatment of neuropathologies associated with FASD and AUD is discussed.
Beyond a neurotransmitter: The role of serotonin in inflammation and immunity.
The existing literature on what is known about the link between 5-HT and the immune system and the effects of 5- HT signaling on different cells of the peripheral immune system are summarized, with a particular focus on T cells.